# Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update
Canonical URL: https://biopharmsignal.com/news/CBIO/gyre-therapeutics-reports-first-quarter-2026-results-and-provides-business-update
Ticker: CBIO
Company: Catalyst Biosciences
Source: Catalyst Biosciences
Published: 2026-05-07 10:00 EST
Original Source URL: https://ir.catalystbiosciences.com
## Summary

Q1 2026 revenue of $22.5 million; GAAP basic EPS: $(0.10) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed NDA for F351 (hydronidone) for CHB-associated liver fibrosis submitted to China’s CDE in March 2026 Completed acquisition of Cullgen in an approximately $300 million

## Article Body
Q1 2026 revenue of $22.5 million; GAAP basic EPS: $(0.10) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed NDA for F351 (hydronidone) for CHB-associated liver fibrosis submitted to China’s CDE in March 2026 Completed acquisition of Cullgen in an approximately $300 million
## Recent Company News
- 2026-05-12 20:06 EST — [Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment](https://biopharmsignal.com/news/CBIO/gyre-therapeutics-announces-nmpa-acceptance-of-new-drug-application-for-f351-hydronidone-for-chb-induced-liver-fibrosis-treatment) — Source: Catalyst Biosciences
- 2026-05-07 10:00 EST — [Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update](https://biopharmsignal.com/news/CBIO/gyre-therapeutics-reports-first-quarter-2026-results-and-provides-business-update) — Source: Catalyst Biosciences
- 2026-03-17 11:00 EST — [Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment](https://biopharmsignal.com/news/CBIO/gyre-therapeutics-announces-china-s-nmpa-grants-priority-review-to-the-nda-for-hydronidone-f351-for-chb-induced-liver-fibrosis-treatment) — Source: Catalyst Biosciences
- 2026-03-12 10:00 EST — [Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update](https://biopharmsignal.com/news/CBIO/gyre-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update) — Source: Catalyst Biosciences
- 2026-03-02 13:00 EST — [Gyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and Pipeline](https://biopharmsignal.com/news/CBIO/gyre-therapeutics-enters-into-agreement-to-acquire-cullgen-to-gain-targeted-protein-degradation-platform-and-pipeline) — Source: Catalyst Biosciences
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)